Abstract Details

Title Obturator Neuropathy: A Retrospective Review of 36 Patients

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P8 - Poster Session 8 (5:30 PM-6:30 PM)

Poster/Presentation
Number 11-008

Objective

The primary objective of this research study is to gain understanding of electrophysiological findings and value of repeat EMG/NCS for prognostication in patients with obturator neuropathy.

Background Obturator neuropathy presents as an uncommon cause of lower extremity weakness with other symptoms including medial thigh numbness, weakness of thigh adduction, and lower extremity pain.

Design/Methods This single center retrospective study aimed to summarize various clinical features of obturator neuropathy. A total of 36 patients with obturator neuropathies diagnosed over a 20-year period, August 2002 to July 2022 were evaluated. Demographic, clinical, and electrographic data were collected, and descriptive statistics were used to analyze the variables of interest. The variables of interest included etiology, symptoms, physical exam signs, time to diagnosis from symptom onset, treatment, age, race, sex, insurance, prognosis, and electromyography (EMG) findings.

Results Of the 36 patients evaluated, surgery related trauma (n=21; 58%) was the most common etiology, and lower extremity pain (n=30; 86%) was the most common symptom. Based on diagnoses made through EMG, 23 patients (79%) had pure obturator neuropathy. Treatments led to improvement or complete resolution in 18 (50%) patients while 11 (31%) had no relief. No significant difference in time to diagnosis was observed based on sex, race, or insurance type.

Conclusions Obturator neuropathies are commonly associated with lower extremity weakness leading to difficulties in ambulation. Surgical trauma was the most common cause in our patient group, followed by cancer related causes. Electrodiagnostic findings, mainly EMG studies, aid in the definitive diagnosis. The lack of statistically significant differences between race, sex, or insurance in our patient group suggests an equitable process of evaluation of patient from their initial presentation with a provider to a definitive diagnosis. The lack of symptomatic improvement in 31% of patients in our group demonstrates the continued need for advancements in nerve repair and regrowth.

Authors/Disclosures
Samuel Goorman (Wayne State University - - Detroit, MI) PRESENTER	Mr. Goorman has nothing to disclose.
Iram Zaman, DO, FAAN (Henry Ford Hospital)	Dr. Zaman has nothing to disclose.
Lonni Schultz, PhD (Henry Ford Hospital)	Dr. Schultz has nothing to disclose.
Anza B. Memon, MD, FAAN (Wayne State University, SOM, Detroit, MI)	Dr. Memon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inlightened. Dr. Memon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Connected Research. Dr. Memon has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutic . The institution of Dr. Memon has received research support from Genentech. The institution of Dr. Memon has received research support from TG Therapeutics.
Elizabeth Ho	Ms. Ho has nothing to disclose.

��ɫ��

��ɫ��